NeuBase announces $5M registered direct offering at $2.57 per share

NeuBase Therapeutics announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 578,697 of its shares of common stock in a registered direct offering at a purchase price of $2.57 per share and associated unregistered warrants. In a concurrent private placement, NeuBase has also agreed to issue and sell an aggregate of 1,366,829 of its shares of common stock at the same purchase price of $2.57 per share and associated unregistered warrants as in the registered direct offering. The registered direct offering and the private placement were priced at-the-market under Nasdaq rules. H.C. Wainwright is acting as the exclusive placement agent for the offerings. The offerings are expected to close on or about June 30. The gross proceeds to the company from the concurrent offerings are expected to be approximately $5M, before deducting the placement agent’s fees and other offering expenses payable by NeuBase.